MD SB793

Licensed health care providers issuing standing orders for opioid overdose reversal drugs must allow individuals to choose any formulation of any FDA-approved overdose reversal drug

Authorized private and public entities that prescribe and dispense overdose reversal drugs are not required to stock or dispense all FDA-approved formulations

Applies to health care providers, local health departments, community-based organizations, substance abuse treatment organizations, and other entities addressing drug addiction

Effective October 1, 2025